银屑病性关节炎的生物制剂治疗进展  

Progress in the Treatment of Psoriatic Arthritis with Bi-ological Agents

作　　者：张然[1] 王怡怡 古元霞 李薇[1,2,3,4,5,6,7,8,9] ZHANG Ran;WANG Yiyi;GU Yuanxia;LI Wei(Department of Dermatovenereology,West China Hospital,Sichuan Universily,Chengdu,610041,China)

机构地区：[1]四川大学华西医院皮肤性病科,四川成都610041 [2]中国中西医结合学会银屑病学组 [3]中国医疗保健国际交流促进会皮肤科分会 [4]中国康复医学会银屑病康复学组 [5]中华预防医学会银屑病学组 [6]中国医师协会皮肤性病分会罕见病学组 [7]四川省医学会变态反应学会 [8]四川省医师协会皮肤性病分会 [9]成都市中西医结合学会皮肤性病分会

出　　处：《皮肤科学通报》2020年第5期455-460,M0002,共7页Dermatology Bulletin

摘　　要：银屑病是一种慢性炎症性疾病,约30%的银屑病患者可发展为银屑病性关节炎。目前银屑病性关节炎的治疗目标是控制症状,提高患者生活质量,防止结构损伤和残疾。该病的治疗药物近年来进展迅速,本文就银屑病性关节炎的生物制剂治疗做一综述。Psoriasis is a chronic inflammatory disease,and about 30% of patients with psoriasis may develop into psoriatic arthritis(PsA).The goal of PsA treatment is to control symptoms,improve patients' quality of life,and prevent structural damage and disability.The therapeutic drugs for the disease are changing with each passing day.Therefore,the progress in the treatment of PsA with biological agents was summarized in this review.

关 键 词：银屑病性关节炎 生物制剂 治疗 

分 类 号：R917[医药卫生—药物分析学]